Although the combined analysis of Aβ, t-tau and p-tau can be used to diagnose AD, it is important to characterize the core of biomarkers involved in the prodromal phase of AD but also in the presymptomatic stage of the disease. This evidence concerns the gene MAPT and Alzheimer disease.